The relationship between type 2 diabetes mellitus (T2DM) and periodontal disease is well established — T2DM acts as a grade modifier in periodontitis, amplifying the inflammatory response and impairing tissue healing. Whether this systemic burden translates equally to peri-implant tissues, however, remains a matter of active investigation. This cross-sectional study by Sbricoli et al. set out to quantify the prevalence of peri-implant diseases in diabetic versus non-diabetic patients, providing clinically grounded data for a question that directly affects implant treatment planning in a growing patient population.

The study enrolled 70 patients — 35 with T2DM and 35 non-diabetic controls — hosting a total of 227 implants in function for at least one year. For each patient, clinical and implant-level parameters were recorded, including probing depth, bleeding on probing, suppuration, and radiographic bone loss, allowing classification of peri-implant health, peri-implant mucositis, and peri-implantitis according to current consensus criteria. The two groups were compared for overall prevalence of peri-implant disease and for the individual diagnoses of mucositis and peri-implantitis.

The results are notably counterintuitive. Overall peri-implant disease prevalence was high in both groups — 80% in diabetic patients, 77% in non-diabetic subjects — with no statistically significant difference (p = 0.99). Disaggregating the data yielded the same pattern: peri-implant mucositis was present in 51% of diabetic versus 63% of non-diabetic patients (p = 0.47), and peri-implantitis in 51% versus 43% respectively (p = 0.63). None of these comparisons reached statistical significance.

These findings challenge the assumption that T2DM should be considered an independent risk factor for peri-implant disease in the same way it is for periodontitis. The biological rationale for an association is sound — chronic hyperglycemia promotes oxidative stress, impairs neutrophil function, and accelerates the formation of advanced glycation end-products in connective tissue — yet the clinical data presented here do not translate this theoretical risk into a measurable difference in peri-implant outcomes.

Several important caveats apply. The sample size is modest, limiting statistical power to detect moderate effect sizes. Metabolic control (HbA1c values) and disease duration, two variables that critically modulate diabetes-related tissue damage, are not reported in the abstract and may not have been stratified in the analysis. Additionally, the strikingly high prevalence of peri-implant disease in both groups raises questions about the baseline oral hygiene and maintenance protocols of the study population, which could act as a confounding ceiling effect.

For the practicing implantologist and periodontist, the clinical take-home is nuanced: T2DM alone, particularly when managed, may not substantially elevate peri-implant disease risk beyond what is already driven by plaque control and host factors common to all patients. This does not diminish the importance of rigorous peri-implant maintenance in diabetic patients, but it does suggest that well-controlled T2DM should not be regarded as a contraindication to implant therapy. Larger prospective studies stratifying patients by glycemic control are needed to define risk thresholds with greater precision.